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1. Introduction 
Tuberculosis (TB) is an infectious and transmissible disease caused by Mycobacterium 
tuberculosis and closely related mycobacterial species (M. bovis, M. africanum, and M. microti). 
These species, obligate pathogens, compose what is known as the M. tuberculosis complex. 
Nontuberculous mycobacterial (NTM) species are mycobacterial species other than those 
belonging to the Mycobacterium tuberculosis complex. Nontuberculous mycobacteria are 
generally free-living organisms that are ubiquitous in the environment. There have been 
more than 140 NTM species identified. In 1959, Runyon proposed a classification of NTM 
into four major groups, based on growth rate and colony pigmentation (Runyon EH , 1959). 
There is an increasing number of clinical isolates of NTM in many countries and growing 
awareness of their ability to cause disease (American Thoracic Society [ATS], 2007). 
Nontuberculous mycobacteria are capable of causing a wide range of infections in humans 
with pulmonary NTM disease being the most common, especially in patients with pre-
existent pulmonary disease (ATS, 2007). They are mainly opportunistic pathogens that can 
occasionally cause severe disseminated diseases, especially in patients with systemic 
impairment of immunity. Identification of specific species of NTM is important because of 
the variation in antimicrobial susceptibility and treatment options.  
Nontuberculous mycobacteria can be divided into slowly growing and rapidly growing 
mycobacteria (RGM). The former constitute members of the Runyon group I to group III, 
whereas the latter are equivalent to the members of Runyon group IV. (Table 1) (Runyon 
E, 1965) Pulmonary disease is primarily caused by M. avium complex (MAC) and M. 
kansasii (ATS, 2007). Other species include M. abscessus, M. fortuitum, M. xenopi, M. 
malmoense, M. szulgai, and M. simiae. In contrast to M. tuberculosis, isolation of NTM does 
not necessarily mean that patient has the disease though it can be isolated transiently 
from respiratory specimens. In order to assist clinicians with the difficult task of trying to 
determine if a given NTM species is causing disease to a patient, a set of criteria utilizing 
clinical, radiographic, and microbiologic parameters has been developed. Furthermore, 
the degree of evidence to support the choice of treatment is limited because a few clinical 
trials have been conducted, especially for disease due to less prevalent NTM species.  
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Mycobacterium tuberculosis complex
                 M. tuberculosis
                 M. bovis
                 M. africanum
                 M. microti
Slowly growing mycobacteria
     Runyon Group I, Photochromogenes
                 M. kansasii
                 M. marinum
     Runyon Group II, Scotochromogenes
                 M. gordonae
                 M. scrofulaceum
     Runyon Group III, Non-chromogenes
                 M. avium complex – M. avium, M. intracellulare
                 M. terrae complex
                 M. ulcerans
                 M. xenopi
                 M. simiae
                 M. malmoense
                 M. szulgai
                 M. asiaticum
Rapidly growing mycobacteria
     Runyon group IV
                 M. fortuitum
                 M. chelonae
                 M. abscesus
Table 1. Classification of mycobacterial species commonly causing human disease 
Current guidelines are mainly based on case reports and clinical experience (ATS 2007, 
British thoracic society [BTS], 1999) 
2. Epidemiology and prevalence 
Tuberculosis still remains an important public health problem worldwide, with more than 9 
million new cases of tuberculosis reported every year and decrease of incidence of less than 
1% per year. On the other hand, in the industrialized world, the incidence of M. tuberculosis 
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infections has been decreasing, while the incidence of NTM pulmonary infections is 
increasing. 
Although both M. tuberculosis and NTM cause chronic lung infections, only M. tuberculosis 
spreads from person to person by inhalation of organisms expectorated into the air. 
Nontuberculous mycobacteria infections are not considered contagious. Since reporting 
NTM pulmonary disease to public health departments is not obligatory, the exact number of 
the infected remains unknown. An increase in the frequency of NTM infections and NTM 
pulmonary disease has been indicated in a number of worldwide surveys and population-
based studies during the last few decades (AST, 2007; Maras et al, 2007; Iseman & Marras, 
2008; Henry et al, 2004; Thomson & Yew, 2009).  
Postulated reasons for this increase include a rise in prevalence of HIV infections and other 
acquired immunocompromised states, increased awareness of these organisms as potential 
pathogens, a better understanding of clinical-pathological relationship between host and 
pathogen, advances in methods of detection of the organisms, an aging population (as this is 
often a disease of the elderly), increased survival of patients with predisposing conditions 
such as cystic fibrosis and COPD, and increased environmental exposure (ATS, 2007; 
Thomson & Yew, 2009). 
Nontuberculous mycobacteria disease is not a reportable condition in most countries 
because it is not considered a public health concern on account of unknown or non-existing 
evidence of human-to-human transmission (ATS, 2007). However, the organisms are 
ubiquitous in the environment, oligotrophic  and many NTM pathogens have been isolated 
from potable water where they can be found forming biofilms (Falkingham et al, 2001). 
Mycobacterium avium complex (MAC), Mycobacterium kansasii and RGM such as M. abscessus 
and M. fortuitum constitute the main species associated with human pulmonary disease. 
(ATS, 2007; Thomsen et al, 2002; Martin-Casabona et al, 2004). It has been shown in multiple 
already published studies that geography has a prominent role in the epidemiology of NTM 
pulmonary disease. Thus, M. xenopi is relatively more common in the south-east and in the 
west of Europe (Marusic et al, 2009; van Ingen et al, 2008; Hanry et al, 2004; Dailloux et al, 
2006) and in Canada (Varadi & Marras, 2009), while M. malmoense is relatively more 
common in the north of Europe (Abgueguen et al, 2010; Petrini, 2006; Thomsen et al, 2002; 
Henry et al, 2004). 
3. Pulmonary disease characteristics and population at risk 
The symptoms of NTM pulmonary disease are variable and nonspecific. Common 
symptoms are chronic or recurring cough, while others such as sputum production, fatigue, 
malaise, dyspnea, fever, hemoptysis and weight loss become more prevalent with advanced 
NTM lung disease.  
Pulmonary NTM disease has three distinct presentations: cavitary disease (resembling 
conventional tuberculosis) (Figure 1) (Moore, 1993; Patz et al, 1995; Jeong et al, 2004), 
nodular-bronchiectatic disease (Figure 2) commonly affecting the right middle lobe and 
lingula (Moore, 1993; Patz et al, 1995; Jeong et al 2004; Reich & Johnson, 1992) and the rarest 
form - hypersensitivity pneumonitis. There are mixed disease forms with infiltrates, nodes, 
bronchiectasis and interstitial changes (Figure 3).  
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Fig. 1. Extensive infiltrate with cavitation in the left lung 
 
Fig. 2. Nodular-bronchiectatic disease in the middle lobe and lingula 
 
Fig. 3. Mixed disease form; infiltrate, nodes, bronchiectasis, “ground glass” interstitial 
pattern and tiny centrilobular nodes in left lower lobe 
HIV-positive and other immunodeficient patients, on the other hand, often have hilar and 
mediastinal lymphadenopathy with systemic spread but without pulmonary infiltrate (dos 
Santos et al, 2008). Patients with NTM pulmonary disease often have predisposing 
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structural lung disease, i.e. chronic obstructive pulmonary disease, cystic fibrosis, 
bronchiectasis, pneumoconiosis, prior tuberculosis, alveolar proteinosis, or chronic 
aspiration (ATS, 2007; Field & Cowie, 2006).  
Among women with pulmonary disease, there is often constellation of physical findings 
such as bronchiectasis, thin body habitus and mitral valve prolapse (Prince et al, 1989; Kim 
et al, 2008). The reason for this association has not been determined and no significant 
immunological abnormality has been identified.  
4. Diagnosis of NTM pulmonary infections 
Patients seeking treatment who have respiratory samples positive for acid-fast bacilli 
(AFB) present a public health dilemma. Although Mycobacterium tuberculosis and NTM 
cause chronic lung infections, only tuberculosis (TB) spreads from person to person by 
inhalation of organisms expectorated into the air, while NTM infections are acquired 
directly from the environment. Diagnosing mycobacterial infections is often quite a 
challenge. Under the microscope, NTM and M. tuberculosis appear similar. Careful 
laboratory investigations must be performed to differentiate them. The definitive 
identification of mycobacterial species, which can take several weeks, and the inability to 
quickly distinguish NTM from TB on clinical grounds makes it difficult for public health 
officials to make decisions regarding contact investigations and isolation. Mycobacterial 
pulmonary disease usually progresses slowly, and clinical diagnosis starts with the 
exclusion of other possible causes. Differential diagnosis includes tuberculosis and fungal 
infection, especially the classical form of NTM infection which mimics M. tuberculosis 
infection. The development and use of molecular techniques to differentiate between the 
mycobacteria strains made it possible to solve some of these problems. The first step in 
diagnosing an NTM infection is suspecting an underlying cause of the symptoms or 
radiographic findings. Chronic cough (lasting >3 weeks), fatigue, night sweats, and 
weight loss should make clinicians consider mycobacterial infections. Even though 
dyspnoea is usually more related to underlying lung disease, occasionally patients with 
the nodular/bronchiectatic disease can have bronchiolitis and air trapping associated 
with dyspnoea. Haemoptysis occurs in more advanced lung disease, especially with 
cavitations and advanced bronchiectasis. A chest radiograph, or more likely, high 
resolution computed tomography (HRCT), could show some radiomorphologic changes 
to be the first sign of presence of an NTM infection. Respiratory specimens should be 
obtained and sent for mycobacterial culture.  
4.1 Imaging of NTM pulmonary infections 
A chest radiograph is the first method to be used when suspecting an NTM pulmonary 
disease but it may be adequate for evaluating only patients with fibrocavitary disease. It is 
widely available and convenient and exposes patient to a very low irradiation dose. On the 
other hand, chest radiograph is far less sensitive and specific than HRCT, especially in 
detection of bronchiectasis, small nodules and other interstitial lung changes. Since 
nodular/bronchiectatic form of pulmonary NTM infection is not rare, HRCT should be used 
in patients with high clinical suspicion even if chest x-ray finding is normal. In case of 
clinical suspicion of hypersensitivity pneumonitis, HRCT is definitively the only method of 
choice. Even though some differences have been reported, it is impossible to differentiate 
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NTM pulmonary disease from TB pulmonary disease relying on radiographic appearance 
alone. Compared with radiographic findings in TB, patients with NTM disease and 
predominantly fibrocavitary radiographic changes tend to have following characteristics: 
thin-walled cavities with less surrounding parenchymal opacity, more contiguous spread of 
disease, and production of more marked involvement of pleura over the involved area of 
the lungs (ATS, 2007). Basal pleural disease is not often found and pleural effusion is rare 
(ATS, 2007). At patients with predominantly nodular/bronchiectatic disease, the 
abnormalities on chest radiograph and HRCT are primarily found in the mid and lower 
lung field. Radiographic follow-up during the treatment should be performed using either 
chest radiograph in patients with predominantly cavitary disease, or HRCT in those with 
interstitial form of the disease. Confirmation of complete resolution and an insight into 
possible residual scarring can be done only by using HRCT. 
4.2 Laboratory features of NTM 
Using modern microbiology laboratory methods, including liquid culture media, NTM 
growth can be detected by culture from a patient’s specimens 1-3 weeks after the incubation. 
(Leitritz et al, 2001) Most rapid growing NTM will grow in 7-10 days. Slow growers can 
grow in 1-3 weeks, but may take much longer. Therefore, cultures are usually kept for 6-8 
weeks before being regarded as negative. At patients colonized with Pseudomonas aeruginosa 
or other bacterial pathogens, sputum specimens can be overgrown before NTM growth 
appears. Special decontamination methods are often necessary to reduce this overgrowth, 
but decontamination also reduces the yield of mycobacteria and persistence is required if 
there is a high clinical suspicion of NTM disease with these patients. With the recovery of an 
organism by culture, DNA probes are commercially available to identify some of the NTM 
(Tortoli et al, 2010).  
Other organisms have traditionally been identified by combination of biochemical testing, 
high-performance liquid chromatography (HPLC) and genetic sequencing of conserved 
regions. Partial sequencing of a segment of 16S ribosomal RNA has been used to identify 
those species not identified by other means. (Cloud et al, 2002, 2005) Current guidelines of 
American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) (ATS, 2007) 
state that routine testing of MAC species for antimicrobial susceptibility (other than 
clarithromycin) is generally not recommended because of the paucity evidence correlating in 
vitro and in vivo results (ATS, 2007). They do recommend clarithromycin susceptibility 
testing for new, previously untreated MAC isolates as macrolide resistance has been 
associated with a poorer outcome. It should also be performed for MAC isolates from 
patients who have relapsed from apparently successful treatment or those who have failed 
macrolide treatment (ATS, 2007). Previously untreated M. kansasii strains should be tested in 
vitro to rimfapicin only (ATS 2007) and against a panel of secondary agents if shown to be 
resistant to rimfapicin. RGM should be tested against a panel of eight antimicrobials, 
including clarithromycin, amikacin, cefoxitin, ciprofloxacin, doxycicline, linezolid, 
sulphamethoxazole and tobramycin.  
4.3 Diagnostic criteria 
Even after an NTM has been isolated and identified, the patient may still not have the 
disease because NTM can be isolated transiently from respiratory specimens. In order to 
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help clinicians with the difficult task of trying to determine if a given NTM species is 
causing disease in a patient the ATS/IDSA developed a set of criteria that utilized clinical, 
radiographic, and microbiologic parameters (ATS, 2007) (Table 2).  
 
Clinical criteria 
          Compatible respiratory symptoms 
          Appropriate exclusion of other diagnoses, especially tuberculosis and mycosis 
AND 
Radiographic criteria 
          Nodular or cavity opacities on chest radiograph, or  
          a HRCT scan that shows multifocal bronchiectasis with or without 
          multiple small nodules 
AND 
Microbiological criteria  
          Positive culture results from at least two or three separately expectorated 
          sputum samples with positive or negative AFB smear, respectively 
OR 
          Positive culture results from at least one bronchial wash or lavage 
OR 
          Transbronchial or other lung biopsy with mycobacterial histopatological 
          features and one positive sputum culture for NTM  
Table 2. Summary of the ATS/IDSA criteria for diagnosis of pulmonary NTM diseases 
The significance of an isolate also varies with the species of mycobacteria. Isolation of 
mycobacteria like M. gordonae, M. flavescens, M. terrae complex or M. triviale usually indicates 
transient colonization or possible contamination of the sample. However, M. szulgai is rarely 
isolated from the environment and a single positive culture provides pathological 
significance (ATS, 2007).  
5. Treatment and prognosis of NTM pulmonary infections 
The currently used regimen for TB treatment consists of four drugs:  rifampin (RIF), 
isoniazid (INH), pyrazinamide (PZA), and ethambutol (EMB), for the duration of six to nine 
months. Treatment of pulmonary NTM infections is usually more complicated than 
treatment of tuberculosis. Drugs, administration frequency, and duration of therapy will 
vary depending on species of NTM causing the disease, extent and the site of infection. 
Some antituberculosis drugs are also active against some NTM species. However, treatment 
of most NTM species also requires administration of antibiotics that are not typically used to 
treat tuberculosis. The prognosis for NTM pulmonary disease depends on specific species 
and subspecies involved and their drugs susceptibility pattern, presence of other medical 
problems and whether or not patient can tolerate the treatment regimen. Cure rate for the 
disease caused by M. kansasii is similar to M. tuberculosis round 90%, while that for the 
disease caused by M. avium is 30-85%. Complete recovery is seldom achieved in patients 
with pulmonary M. abscessus infection (ATS, 2007).  
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Diagnosing pulmonary NTM infection/disease does not equate the need for immediate 
treatment since treatment usually involves combination antibiotic therapy for 12-24 months 
and constitutes an important undertaking for the patient. Lung involvement may range in 
severity from mild clinical (indolent) infection to disease associated with extensive invasion 
or destruction of the lungs. In some cases the disease remits spontaneously. Most of the 
early studies on NTM covered MAC, M. kansasii and M. abscessus and developed diagnostic 
criteria and treatment regimens best suitable for these species. There is not enough 
knowledge about most other NTM to be certain that the diagnostic criteria are universally 
applicable for all NTM respiratory pathogens (ATS, 2007). Generally, patients respond best 
to NTM treatment first time it is administered. Therefore, it is important that patients 
initially receive a recommended multi-drug regimen (ATS, 2007).  
The British Thoracic Society (BTS) and ATS/IDSA have published guidelines for the 
management of the disease caused by NTM. Guidelines published by ATS/IDSA have been 
updated in 2007 providing an extensive review of the available literature on NTM disease 
combined with expert opinion. The recommended criteria are thus based on several smaller 
prospective non-randomized controlled studies at the US patients.  
It is very difficult to compare many different studies in pulmonary NTM disease 
considering the geographic differences in patient populations, mixture of disease types, 
severity of disease, differing species of NTM, drugs and therapy protocols used and 
different study design and analysis. The BTS guidelines are predominantly based on two 
large randomized controlled trials performed in patients of the UK and Europe (BTS, 2001). 
All of the mentioned differences are factors contributing to the significant heterogeneity of 
findings and hence the recommendations made by the Societies.  
Treatment of pulmonary disease should be considered in patients who meet clinical, 
radiological, and microbiologic criteria for NTM disease. Two main factors to consider 
regarding initiation of therapy should be pathogenicity of species and rate of disease 
progression. Therapy for NTM requires prolonged administration of multiple drugs and is 
associated with significant side effects. The decision to institute treatment in patients with 
non-cavitary disease who do not have clearly progressive pulmonary disease should be 
made carefully, after a period of clinical and radiological follow-up. The aim of therapy is a 
12-month period of negative sputum cultures.  
5.1 Specific antimicrobial treatment guidelines 
5.1.1 MAC lung disease 
Recommended treatment regimens for MAC lung disease are summarized in Table 3. There 
are still a number of controversies and unresolved questions regarding the management of 
MAC lung disease.  
First, there is no demonstrated superiority of one macrolide among the two agents 
regarding efficacy or risk of resistance. It seems that macrolides have helped improving 
treatment of MAC lung disease (Kobashi YMT, 2004) though not all studies have supported 
this (Jenkins et al, 2008).  
Second, there has also been no demonstrated superiority of one rifamycin (rifabutin or 
rifampicin) in the treatment of MAC lung disease, but because of frequent adverse events,  
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Nodular/bronchiectatic disease  
All given 3 times weekly 
Clarithromycin (1000 mg) or azithromycin 
(500 mg) + 
Rifampin (600 mg) + 
Ethambutol (25 mg/kg) 
Fibrocavitary MAC lung disease or severe 
nodular/bronchiectatic disease 
 
All given daily 
Clarithromycin (500–1000 mg) or 
azithromycin (250 mg) + 
Rifampin (600 mg) or  
rifabutin (150–300 mg) + 
Ethambutol (15 mg/kg) 
 
Consider adding 3-times-weekly amikacin or 
streptomycin early in therapy (e.g., for the 
first 8 weeks) 
Duration: 
Treat until cultures have been negative on 
therapy for 1 year. 
Table 3. Recommended treatment regimens for MAC pulmonary disease 
most experts recommend the use of rifampicin (Griffith et al, 1995) Regarding the use of 
an amynoglicoside in the initial phase of treatment, the majority of early macrolides 
studies performed in the USA included 2- to 3-month period of intermittent 
amynoglicoside. Furthermore, Kobashi has shown that sputum conversion rates, relapse 
rates and overall outcomes were better in the cohort that received amynoglicoside 
(Kobashi YMT, 2004).  
For hypersensitivity pneumonitis due to MAC, removal from environmental exposure is 
mandatory. Corticosteroids and/or anti-microbial drugs might be required in some cases 
and usually a shorter regimen of 3-6 months may be appropriate. (Hanak et al, 2006) 
5.1.2 M. kansasii lung disease 
Recommended treatment regimen for M. kansasii lung disease is summarized in Table 4. For 
susceptible strains, rifampin is the foundation of a multiple-drug regimen. Resistance to 
rifampin may develop, in which case a 3-drug regimen should be chosen on the basis of in 
vitro susceptibility testing (e.g., clarithromycin or azithromycin, moxifloxacin, ethambutol, 
sulphamethoxazole, or streptomycin) (ATS 2007). 
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5.1.3 M. xenopi, M. malmoense and M. szulgai lung disease 
M. xenopi has variable drug susceptibility testing results, especially regarding the first-line 
antituberculotic agents (ATS, 2007). The clinical response to treatment does not always 
correlate well with drug susceptibility testing results. The ATS proposed regimen is a 
combination of ethambutol, rifampicin, isoniasid and clarithromycin with or without an 
initial course of streptomycin. M. malmoense can be difficult to treat. A combination of 
rifampicin and ethambutol with or without isoniasid has shown some effectiveness (BTS 
2001). M. szulgai is susceptible in vitro to most antituberculosis drugs, as well as to 
floroquinolones and macrolides (Sanchez-Alarcos et al, 2003) and a 3- or 4-drug regimen 
that includes 12 months of negative sputum cultures while on therapy is recommended 
(ATS, 2007) 
 
Rifampin 600 mg/d, + 
Isoniazid 300 mg/d, + 
Ethambutol 15 mg/kg/d 
Duration: at least 12 months after the last positive sputum culture 
Table 4. Recommended treatment regimens for rifampicin-susceptible Mycobacterium kansasii 
pulmonary disease 
5.1.4 Lung disease caused by rapidly growing mycobacteria 
Three main species of RGM causing pulmonary disease are M. abscessus, M. chelonae and M. 
fortuitum. The choice of treatment relies on guidance from susceptibility testing as there are 
no results from large-scale clinical studies available. M. abscessus pulmonary disease can be 
especially difficult to treat.  
The treatment usually involves combination of amikacin, cefoxitin/imipenem and 
clarithromycin. The summary of proposed treatment for RGM lung disease is shown in 
Table 5. For many patients, realistic objectives of treatment are to help controlling symptoms 
and disease progression rather than curing the infection. Surgery can be considered for 
localized disease. 
5.1.5 Surgical treatment 
Surgical resection of limited (focal) pulmonary NTM disease in a patient with an adequate 
cardiopulmonary reserve can be successful in combination with multi-drug treatment 
regimens for MAC and M. abscessus disease (ATS, 2007). In addition, in an extensive disease, 
the excision of large cavitary mycobacterial foci might assist medical management of 
remaining lesions. However, according to ATS guidelines, surgery should only be 
performed in medical centres with considerable medical and surgical expertise in 
management of patients with NTM disease.  
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M. abscessus 
Active drugs Surgery 
Clarithromycin 
++ 
Amikacin 
Cefoxitin 
Imipenem 
M. chelonae 
Tobramycin 
+ 
Clarithromycin 
Linezolid 
Imipenem 
Amikacin 
Doxycycline 
Ciprofloxacin 
M. fortuitum 
Amikacin 
+ 
Ofloxacin/Ciprofloxacin 
Imipenem 
Sulphonamides 
Clarithromycin 
Doxycycline 
Table 5. Treatment of lung disease due to rapidly growing mycobacteria 
6. Where do we go from here? 
Given the recent worldwide increase in NTM infections and in comparison to other lung 
diseases, relatively little progress has been made in understanding, preventing or treating 
pulmonary NTM disease. It is still not clear why some people develop infections while most 
do not. Even though information is provided from basic research and a few clinical trials, 
better understanding of the pathogenesis of these infections is needed in order to improve 
prevention of harm from these ubiquitous environmental bacteria. As NTM lung diseases 
are generally difficult to treat, new drugs are needed to advance therapy. Furthermore, 
randomized controlled trials in well-described patients would provide stronger evidence-
based data to guide therapy of NTM lung diseases. Elucidation of the mechanism behind 
host susceptibility will also add invaluable information so that therapy could be directed 
towards the underlying cause for the establishment of infection. Finally, environmental 
factors contributing to the increased prevalence of infection should also be explored in order 
to reduce infection and re-infection of susceptible patients.  
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